I am a second year Master’s student in Molecular Medicine and Bioengineering. I am representing my laboratory, Antibody Engineering and Protein Therapeutics Lboratory under Prof. Yu-Cheng Su, at the event. Our research focus on engineering bispecific antibodies for targeted delivery of nanomedicines to improve anticancer selectivity and development of novel bispecific antibodies to deliver nanomedicines across blood-brain barrier.
Structure-Guided Engineering of a High-affinity anti-Methoxy Polyethylene Glycol Antibody for Sensitive Immunosensing of mPEGylated Therapeutics
Chiao-Yu Hsiao 1, Jun-Lun Meng 1, Jung-Zhe Hong 1, Meng-Hsuan Lin 1, Minh-Tram T. Nguyen1, Yu-Cheng Su*
Sensitive quantification of methoxy poly(ethyleneglycol) (mPEG)-conjugated therapeutics for pharmacokinetic determination is critical for mPEGylated drug development. However, sensitive measurement of low-molecular-weight (lmw) mPEG compounds remains challenging due to epitope competition between backbone-specific anti-PEG antibodies. Here, we engineered a high-affinity methoxy-specific anti-mPEG antibody for sensitive quantification of free mPEG molecules and mPEGylated therapeutics. The affinity-enhanced h15-2Y antibody variant shows a 10.3-fold increase in mPEG-binding activity compared to parental h15-2b. h15-2Y-based sandwich ELISA can effectively quantify lmw mPEG5K and high-molecular-weight (hmw) mPEG20K at concentrations as low as 3.4 and 5.1 ng mL−1, respectively. Moreover, lmw mPEG compounds (560, 750, 1000, and 2000 Da) can be efficiently quantified via h15-2Y-based competitive ELISA with detection limits at nanomolar levels. This study provides a promising approach for application in the quantitative analysis of the various sizes of mPEG molecules to accelerate the timeline of mPEG-conjugated drug development.